Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Werewolf Therapeutics Inc
(NQ:
HOWL
)
2.070
+0.050 (+2.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
163,045
Open
1.990
Bid (Size)
1.930 (4)
Ask (Size)
2.230 (4)
Prev. Close
2.020
Today's Range
1.965 - 2.120
52wk Range
1.573 - 8.194
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
HOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Beats Revenue for Q2 2024
August 08, 2024
HOWL stock results show that Werewolf Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
-55.39%
-55.39%
1 Month
-28.12%
-28.12%
3 Month
-56.14%
-56.14%
6 Month
-69.96%
-69.96%
1 Year
-16.36%
-16.36%
More News
Read More
Where Werewolf Therapeutics Stands With Analysts
June 26, 2024
Via
Benzinga
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
June 25, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
June 03, 2024
Via
Benzinga
Critical Insights From Werewolf Therapeutics Analyst Ratings: What You Need To Know
May 24, 2024
Via
Benzinga
The Analyst Verdict: Werewolf Therapeutics In The Eyes Of 4 Experts
May 06, 2024
Via
Benzinga
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
June 01, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
May 30, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
May 23, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Recap: Werewolf Therapeutics Q4 Earnings
March 07, 2024
Via
Benzinga
HOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Misses Revenue for Q1 2024
May 03, 2024
Via
InvestorPlace
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 03, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
April 23, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
April 05, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
April 04, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
HOWL Stock Earnings: Werewolf Therapeutics Beats EPS, Misses Revenue for Q4 2023
March 07, 2024
Via
InvestorPlace
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 07, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
March 06, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
March 05, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
January 08, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
January 04, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
January 04, 2024
Via
Benzinga
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
November 22, 2023
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.